SAR analysis of new dual targeting fluoroquinolones. Implications of the benzenesulfonyl group

Medicinal Chemistry

Volumn 8, Issue 3, 2012, Pages 349-360

  Nieto, Marcelo J ^a   Pierini, Adriana B ^b   Singh, Nidhi ^c   McCurdy, Christopher R ^c   Manzo, Ruben H ^b   Mazzierie, María R ^b  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Benzenesulfonyl group; Conformational analysis; Fluoroquinolones; Pharmacophore; QSAR

Indexed keywords

BENZENECARBOXAMIDE FLUOROQUINOLONE; BENZENESULFONYL FLUOROQUINOLONE; CARBONYL DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; CONTROLLED STUDY; DIFFUSION; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; IN VITRO STUDY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BENZYL COMPOUNDS; COMPUTATIONAL BIOLOGY; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STAPHYLOCOCCUS AUREUS;

EID: 84863691058     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340612800786633     Document Type: Article

References (52)

1. Pan, X.-S.; Hamlyn, P.J.; Talens-Visconti, R.; Alovero, F.L.; Manzo, R.H.; Fisher, L.M. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dualtarget fluoroquinolones. Antimicrob. Agents Chemother., 2002, 46(8), 2498-2506. (Pubitemid 34793455)
2. Strahilevitz, J.; Hooper, D.C. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using wck-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob. Agents Chemother., 2005, 49(5), 1949-1956. (Pubitemid 40631611)
3. Hooper, D.; Rubinstein, E. Quinolone antimicrobial agents, 3rd edition, 2002.
4. Shen, L.L.; Mitscher, L.A.; Sharma, P.N.; O'Donnell, T.J.; Chu, D.T.W.; Cooper, C.S.; Rossen, T.; Pernet, A.G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model. Biochemistry, 1989, 28, 3886-3894. (Pubitemid 19125438)
5. Allemandi, D.A.; Alovero, F.L.; Manzo, R.H. In-vitro activity of new sulfanilyl fluoroquinolones against Staphylococcus aureus. J. Antimicrob. Chemother., 1994, 34(2), 261-265.
6. Manzo, R.H.; Allemandi, D.A.; Perez, J.D. Antibacterial 7-[4-[(4-aminophenyl)sulfonyl]-1-piperazinyl]-6-fluoro-1,4-dihydro-4- oxoquinoline-3-carboxylic acid derivatives and synthesis thereof. US5395936, 1995.
7. Alovero, F.; Nieto, M.; Mazzieri, M.R.; Then, R.; Manzo, R.H. Mode of action of sulfanilyl fluoroquinolones. Antimicrob. Agents Chemother., 1998, 42(6), 1495-1498. (Pubitemid 28257657)
8. Nieto, M.J.; Alovero, F.L.; Manzo, R.H.; Mazzieri, M.R. A new class of fluoroquinolones: Benzenesulfonamidefluoroquinolones (BSFQs), antibacterial activity and SAR studies. Eur. J. Med. Chem., 1999, 34(3), 209-214.
9. Nieto, M.J.; Alovero, F.L.; Manzo, R.H.; Mazzieri, M.R. Benzenesulfonamide analogs of fluoroquinolones. Antibacterial activity and QSAR studies. Eur. J. Med. Chem., 2005, 40(4), 361-369. (Pubitemid 40460298)
10. Alovero, F.; Barnes, A.; Nieto, M.; Mazzieri, M.R.; Manzo, R.H. Comparative study of new benzenesulphonamide fluoroquinolones structurally related to ciprofloxacin against selected ciprofloxacinsusceptible and -resistant Gram-positive cocci. J. Antimicrob. Chemother., 2001, 48(5), 709-712. (Pubitemid 33100317)
11. Alovero, F.L.; Pan, X.-S.; Morris, J.E.; Manzo, R.H.; Fisher, L.M. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at c-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother., 2000, 44(2), 320-325. (Pubitemid 30060726)
12. Nieto, M.J.; Alovero, F.L.; Manzo, R.H.; Mazzieri, M.R. Benzenecarboxamide analogs of fluoroquinolones (BCFQs). Antibacterial activity and sar studies. Lett. Drug Des. Discov., 2006, 3(2), 108-111.
13. Accelrys Catalyst, 48; Accelrys: Burlington, MA.
14. Schaftenaar, G.; Noordik, J.H. Molden: A pre- and post-processing program for molecular and electronic structures. J. Comp.Aided Mol. Des., 2000, 14(2), 123-134. (Pubitemid 30110670)
15. Dewar, M.J.S.; Zoebisch, E.G.; Healy, E.F.; Stewart, J.J.P. Development and use of quantum mechanical molecular models. 76. Am1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc., 1985, 107(13), 3902-3909.
16. Semichem, I. Ampac 8, AMPAC 8; Semichem, Inc.: Shawnee, KS 66222., 1992-2004.
17. Stewart, J.P.P. Winmopac, Fujitsu Limited: Tokyo, Japan, 1997.
18. StatSoft Statistica, 4.1; StatSoft: Tulsa, OK, 2005.
19. Gund, P. Three-dimensional pharmacophoric pattern searching. Prog. Mol. Subcell. Biol., 1977, 5, 117-143.
20. Brooks, B.R.; Bruccoleri, R.E.; Olafson, B.D.; States, D.J.; Swaminathan, S.; Karplus, M. Charmm: A program for macromolecular energy, minimization, and dynamics calculations. J. Comp. Chem., 1983, 4(2), 187-217.
21. Smellie, A.; Teig, S.L.; Towbin, P. Poling: Promoting conformational variation. J. Comp. Chem., 1995, 16(2), 171-187.
22. Fisher, R.A. The design of experiments. 9th ed. Hafner Publishing Company: New York, NY, 1971.
23. De Benedetti, P.G.; Iarossi, D.; Folli, U.; Frassineti, C.; Menziani, C.; Cennamo, C. Quantitative structure activity relationships in dihydropteroate synthase inhibition by multisubstituted sulfones. Design and synthesis of some new derivatives with improved potency. J. Med. Chem., 1989, 32, 2396-2399. (Pubitemid 19245906)
24. De Benedetti, P.G.; Iarossi, D.; Menziani, C.; Caiolfa, V.; Frassineti, C.; Cennamo, C. Quantitative structure-activity analysis in dihydropteroate synthase inhibition by sulfones. Comparison with sulfanilamides. J. Med. Chem., 1987, 30, 459-464. (Pubitemid 17033649)
25. De Benedetti, P.G. Molecular modeling and quantitative structureactivity analysis of antibacterial sulfanilamides and sulfones. Prog. Drug Res., 1991, 36, 361-417.
26. Ohta, M.; Koga, H. Three dimensional structure-activity relationships and receptor mapping of n1-substituents of quinolone antibacterials. J. Med. Chem., 1991, 34, 131-139.
27. Chung, S.K.; Sun, J.H. Geometry mapping of n(1)-substituents of quinolone antibacterials and the antibacterials mode of actions. Korean J. Med. Chem., 1993, 3, 148-161.
28. Turel, I.; Leban, I.; Klintschar, G.; Bukovec, N.; Zalar, S. Synthesis, crystal structure, and characterization of two metal-quinolone compounds. J. Inorg. Biochem., 1997, 66, 77-82. (Pubitemid 27169360)
29. Menziani, M.C.; Cocchi, M.; De Benedetti, P.G. A molecular dynamics simulation of sequence-directed recognition peptides interacting with bigendothelin. J. Mol. Struct., 1993, 286, 95-108.
30. Liang, G.; Bays, J.P.; Bowen, J.P. Ab initio calculations and molecular mechanics (mm#) force field development for sulfonamide and its alkyl derivatives. J. Mol. Struct., 1997, 401, 165-179. (Pubitemid 127400208)
31. Nieto, M.J.; Alovero, F.L.; Manzo, R.H.; Mazzieri, M.R. A new clas of fluoroquinolones: Benzenesulfonamidefluoroquinolones (BSFQs). Antibacterial activity and sar studies. Eur. J. Med. Chem., 1999, 34(3), 209-214.
32. Reuman, M.; Daum, S.J.; Singh, B.; Wentland, M.P.; Perni, R.B.; Pennock, P.; Carabateas, P.M.; Gruett, M.D.; Saindane, M.T.; et al. Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7- pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents. J. Med. Chem., 1995, 38(14), 2531-2540.
33. Gordeev, M.F.; Hackbarth, C.; Barbachyn, M.R.; Banitt, L.S.; Gage, J.R.; Luehr, G.W.; Gomez, M.; Trias, J.; Morin, S.E.; Zurenko, G.E.; Parker, C.N.; Evans, J.M.; White, R.J.; Patel, D.V. Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett., 2003, 13(23), 4213-4216. (Pubitemid 37410315)
34. Hubschwerlen, C.; Specklin, J.-L.; Sigwalt, C.; Schroeder, S.; Locher, H.H. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg. Med. Chem., 2003, 11(10), 2313-2319. (Pubitemid 36457859)
35. Butler, M.M.; LaMarr, W.A.; Foster, K.A.; Barnes, M.H.; Skow, D.J.; Lyden, P.T.; Kustigian, L.M.; Zhi, C.; Brown, N.C.; Wright, G.E.; Bowlin, T.L. Antibacterial activity and mechanism of action of a novel anilinouracil- fluoroquinolone hybrid compound. Antimicrob. Agents Chemother., 2007, 51(1), 119-127. (Pubitemid 46047696)
36. Robertson, G.T.; Bonventre, E.J.; Doyle, T.B.; Du, Q.; Duncan, L.; Morris, T.W.; Roche, E.D.; Yan, D.; Lynch, A.S. In vitro evaluation of cbr-2092, a novel rifamycin-quinolone hybrid antibiotic: Studies of the mode of action in Staphylococcus aureus. Antimicrob. Agents Chemother., 2008, 52(7), 2313-2323. (Pubitemid 351915658)
37. Bhanot, S.K.; Singh, M.; Chatterjee, N.R. The chemical and biological aspects of fluoroquinolones reality and dreams. Curr. Pharm. Des., 2001, 7(5), 311.
38. Foroumadi, A.; Mansouri, S.; Kiani, Z.; Rahmani, A. Synthesis and in vitro antibacterial evaluation of N-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2- yl] piperazinyl quinolones. Eur. J. Med. Chem., 2003, 38(9), 851-854. (Pubitemid 37244048)
39. Llorente, B.; Leclerc, F.; Cedergren, R. Using sar and qsar analysis to model the activity and structure of the quinolone-DNA complex. Bioorg. Med. Chem., 1996, 4(1), 61-71. (Pubitemid 26079561)
40. Domagala, J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother., 1994, 33(4), 685-706. (Pubitemid 24149805)
41. Koga, H.; Itoh, A.; Murayama, S.; Suzue, S.; Irikura, T. Structureactivity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J. Med. Chem., 1980, 23(12), 1358-1363. (Pubitemid 11164105)
42. Emami, S.; Shafiee, A.; Foroumadi, A. Structural features of new quinolones and relationship to antibacterial activity against Grampositive bacteria. Mini Rev. Med. Chem., 2006, 6(4), 375-386.
43. Foroumadi, A.; Emami, S.; Mehni, M.; Moshafi, M.H.; Shafiee, A. Synthesis and antibacterial activity of n-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and n-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones. Bioorg. Med. Chem. Lett., 2005, 15(20), 4536-4539. (Pubitemid 41253889)
44. Mitscher, L.A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev., 2005, 105(2), 559-592. (Pubitemid 40351634)
45. Van Bambeke, F.; Michot, J.M.; Van Eldere, J.; Tulkens, P.M. Quinolones in 2005: An update. Clin. Micr. Infect., 2005, 11(4), 256-280. (Pubitemid 40443832)
46. Peterson, L.R. Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity. Clin. Infect. Dis., 2001, 33 (Suppl 3), S180-186. (Pubitemid 32835789)
47. Kerns, R.J.; Rybak, M.J.; Kaatz, G.W.; Vaka, F.; Cha, R.; Grucz, R.G.; Diwadkar, V.U. Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett., 2003, 13(13), 2109-2112. (Pubitemid 36694285)
48. Kerns, R.J.; Rybak, M.J.; Kaatz, G.W.; Vaka, F.; Cha, R.; Grucz, R.G.; Diwadkar, V.U.; Ward, T.D. Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drugresistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett., 2003, 13(10), 1745-1749. (Pubitemid 36561156)
49. Hooper, D.C. Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin. Infect. Dis., 2001, 32, S9.
50. Morrissey, I.; Hoshino, K.; Sato, K.; Yoshida, A.; Hayakawa, I.; Bures, M.G.; Shen, L.L. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob. Agents Chemother., 1996, 40(8), 1775-1784. (Pubitemid 26277792)
51. Piddock, L.J.V.; Jin, Y.F.; Griggs, D.J. Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J. Antimicrob. Chemother., 2001, 47(3), 261-270. (Pubitemid 32229567)
52. Beyer, R.; Pestova, E.; Millichap, J.J.; Stosor, V.; Noskin, G.A.; Peterson, L.R. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob. Agents Chemother., 2000, 44(3), 798-801. (Pubitemid 30117987)